DK2522668T3 - Morphinanforbindelser - Google Patents

Morphinanforbindelser Download PDF

Info

Publication number
DK2522668T3
DK2522668T3 DK12176544.0T DK12176544T DK2522668T3 DK 2522668 T3 DK2522668 T3 DK 2522668T3 DK 12176544 T DK12176544 T DK 12176544T DK 2522668 T3 DK2522668 T3 DK 2522668T3
Authority
DK
Denmark
Prior art keywords
compound
composition
formula
disorders
dextromethorphan
Prior art date
Application number
DK12176544.0T
Other languages
English (en)
Inventor
Roger Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2522668T3 publication Critical patent/DK2522668T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine

Claims (12)

  1. MORPHINANFORBINDELSER
    1. Forbindelse med formlen I:
    eller et farmaceutisk acceptabelt salt deraf, hvor: R1 er CD3 og R2 er CH3; til anvendelse i en fremgangsmåde til behandling eller diagnosticering af menneske- eller dyrekroppen.
  2. 2. Forbindelse eller farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1, hvori et hvilket som helst atom, der ikke er betegnet som deuterium, er til stede ved dets naturlige isotophyppighed.
  3. 3. Pyrogen-fri sammensætning omfattende forbindelsen eller det farmaceutisk acceptable salt deraf ifølge et hvilket som helst af de foregående krav og et acceptabelt bærestof.
  4. 4. Sammensætning ifølge krav 3, hvilken sammensætning er formuleret til farmaceutisk administration, og hvor bærestoffet er et farmaceutisk acceptabelt bærestof.
  5. 5. Sammensætning ifølge krav 3 eller 4, hvilken sammensætning endvidere omfatter et andet terapeutisk middel, der er nyttigt i behandlingen eller forebyggelsen af en sygdom eller tilstand, der er udvalgt fra emotionel labilitet; pseudobulbær affekt; autisme; neurologiske forstyrrelser; neurodegenerative sygdomme; hjerneskade; forstyrrelser af bevidsthedslidelser; kardiovaskulære sygdomme; glaukom; tardiv dyskinesi; diabetisk neuropati; retinopatiske sygdomme; sygdomme eller forstyrrelser forårsaget af homocystein-induceret apoptose; sygdomme eller forstyrrelser forårsaget af forhøjede niveauer af homocystein; kronisk smerte; vanskeligt behandlelig smerte; neuropatisk smerte; sympatetisk medieret smerte; smerte i forbindelse med gastrointestinal dysfunktion; epileptiske anfald; tinnitus; seksuel dysfunktion; vanskeligt behandlelig hoste; dermatitis; afhængighedsforstyrrelser; Retts syndrom (RTT); stemmeforstyrrelser på grund af ukontrollerede laryngalmuskelspasmer; methotrexat neurotoksicitet og træthed forårsaget af cancer.
  6. 6. Sammensætning ifølge krav 5 hvor det andet terapeutiske middel er udvalgt fra quinidin, quinidinsulfat, oxycodon og gabapentin.
  7. 7. Separate doseringsformer af: (i) en forbindelse, et farmaceutisk acceptabelt salt deraf eller en sammensætning ifølge et hvilket som helst af kravene 1-4; og (ii) et andet terapeutisk middel, der er nyttigt i behandlingen eller forebyggelsen af en sygdom eller tilstand, der er udvalgt fra emotionel labilitet; pseudobulbær affekt; autisme; neurologiske forstyrrelser; neurodegenerative sygdomme; hjerneskade; forstyrrelser af bevidsthedslidelser; kardiovaskulære sygdomme; glaukom; tardiv dyskinesi; diabetisk neuropati; retinopatiske sygdomme; sygdomme eller forstyrrelser forårsaget af homocysteininduceret apoptose; sygdomme eller forstyrrelser forårsaget af forhøjede niveauer af homocystein; kronisk smerte; vanskeligt behandlelig smerte; neuropatisk smerte; sympatetisk medieret smerte; smerte i forbindelse med gastrointestinal dysfunktion; epileptiske anfald; tinnitus; seksuel dysfunktion; vanskeligt behandlelig hoste; dermatitis; afhængighedsforstyrrelser; Retts syndrom (RTT); stemmeforstyrrelser på grund af ukontrollerede laryngalmuskelspasmer; methotrexat neurotoksicitet og træthed forårsaget af cancer, hvor forbindelsen, det farmaceutisk acceptable salt deraf eller sammensætningen og det andet terapeutiske middel er forbundet med hinanden.
  8. 8. Separate doseringsformer ifølge krav 7, hvor det andet terapeutiske middel er udvalgt fra quinidin, quinidinsulfat, oxycodon og gabapentin.
  9. 9. Pakning omfattende separate doseringsformer ifølge krav 7 eller 8.
  10. 10. Separate doseringsformer eller pakning ifølge et hvilket som helst af kravene 7-9, hvor det andet middel er beregnet til samtidig administration.
  11. 11. Separate doseringsformer eller pakning ifølge et hvilket som helst af kravene 7-9, hvor det andet middel er beregnet til separat administration.
  12. 12. Sammensætning, separate doseringsformer eller pakning ifølge et hvilket som helst af kravene 5-11, omfattende 10-60 mg af forbindelsen med formlen I eller et farmaceutisk acceptabelt salt deraf, og 2,5-30 mg quinidin.
DK12176544.0T 2007-05-01 2008-04-30 Morphinanforbindelser DK2522668T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91513007P 2007-05-01 2007-05-01
US91666207P 2007-05-08 2007-05-08
US97604407P 2007-09-28 2007-09-28
EP11000764.8A EP2357183B1 (en) 2007-05-01 2008-04-30 Morphinan compounds

Publications (1)

Publication Number Publication Date
DK2522668T3 true DK2522668T3 (da) 2015-05-26

Family

ID=51894365

Family Applications (4)

Application Number Title Priority Date Filing Date
DK12176544.0T DK2522668T3 (da) 2007-05-01 2008-04-30 Morphinanforbindelser
DK20200633.4T DK3825306T3 (da) 2007-05-01 2008-04-30 Morphinanforbindelser
DK14173190.1T DK2792662T3 (da) 2007-05-01 2008-04-30 Morphinanforbindelser
DK11000764.8T DK2357183T3 (da) 2007-05-01 2008-04-30 Morphinanforbindelser

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK20200633.4T DK3825306T3 (da) 2007-05-01 2008-04-30 Morphinanforbindelser
DK14173190.1T DK2792662T3 (da) 2007-05-01 2008-04-30 Morphinanforbindelser
DK11000764.8T DK2357183T3 (da) 2007-05-01 2008-04-30 Morphinanforbindelser

Country Status (15)

Country Link
US (6) US9314440B2 (da)
EP (5) EP2792662B1 (da)
BR (1) BRPI0811478B8 (da)
CA (3) CA2945581C (da)
CY (1) CY1117826T1 (da)
DK (4) DK2522668T3 (da)
ES (5) ES2951028T3 (da)
FI (1) FI3825306T3 (da)
HK (5) HK1201058A1 (da)
HR (5) HRP20230745T3 (da)
HU (3) HUE025569T2 (da)
LT (1) LT3825306T (da)
PL (3) PL2357183T3 (da)
PT (5) PT2792662T (da)
SI (2) SI3825306T1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3825306T1 (sl) 2007-05-01 2023-10-30 Sun Pharmaceutical Industries, Inc. Morfinanske spojine
MX341177B (es) * 2007-05-01 2016-08-10 Concert Pharmaceuticals Inc Compuestos de morfina.
US20180243291A1 (en) * 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
WO2017020002A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017064876A1 (ja) 2015-10-14 2017-04-20 学校法人 久留米大学 グレリンを有効成分として含有するレット症候群（ｒｔｔ）の予防・治療剤
AU2018210230A1 (en) 2017-01-19 2019-09-05 Donald Danforth Plant Science Center Morphinan N-demethylase isolated from the Methylobacterium Thebainfresser and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38115A (en) 1863-04-07 Improvement in turning edges of plates or metal sheets
GB713146A (en) 1951-10-18 1954-08-04 Roche Products Ltd Anti-cough agents comprising (ú½)-3-hydroxy-n-methyl-morphinane ethers and process for the manufacture thereof
US4316888A (en) 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
US4446140A (en) 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
JPS6089474A (ja) 1983-10-20 1985-05-20 Toyo Pharma- Kk モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
US4898860A (en) 1985-08-16 1990-02-06 New York University Anticonvulsant composition and method
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5336980A (en) 1992-12-10 1994-08-09 Leopold Kostal Gmbh & Co. Apparatus and method for controlling a windshield wiping system
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
DE69434794T2 (de) 1994-09-22 2007-07-12 Smith, Richard Alan, La Jolla Kombination von dextromethorphan mit quinidine oder quinine sulfat zur behandlung verschiedener refraktärer störungen
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CH690817A5 (de) 1996-09-03 2001-01-31 Flachsmann Ag Emil Verfahren zur Herstellung eines stabilen, homogenen, von Folgeprodukten freien oder nahezu freien Extraktes.
CN1150196C (zh) 1997-03-27 2004-05-19 东丽株式会社 吗啡烷衍生物及医药用途
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
EP1051163A2 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ATE234299T1 (de) 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
WO2001041707A2 (en) 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US6780871B2 (en) 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US6583152B2 (en) 2001-04-30 2003-06-24 Dexgen Pharmaceuticals, Inc. Composition for reducing the risk or progression of cardiovascular diseases
US20040087479A1 (en) 2001-04-30 2004-05-06 Sosnowski Robert E. Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
EP1390063B1 (en) 2001-05-03 2004-11-17 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
UA77234C2 (en) 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
JP5438250B2 (ja) 2002-05-17 2014-03-12 ジェンケン バイオサイエンスィズ，インコーポレイテッド オピオイド及びオピオイド様の化合物並びにそれらの使用
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE102004009445A1 (de) 2004-02-27 2005-09-29 Chemetall Gmbh Verfahren zur Herstellung von Alkyllithiumverbindungen und Aryllithiumverbindungen durch Reaktionsverfolgung mittels IR-Spektroskopie
US7691874B2 (en) 2004-05-14 2010-04-06 Hyoung-Chun KIM Neuroprotective properties of dextrorotatory morphinans
CA2581169A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20070191411A1 (en) 2004-10-07 2007-08-16 Smith Richard A Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor
US7114547B2 (en) 2005-01-11 2006-10-03 Sullivan Michael R Casting ring
CA2615678C (en) 2005-07-26 2015-01-20 Nycomed Gmbh Isotopically substituted pantoprazole
KR101380190B1 (ko) 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
AU2006299424A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
AU2007285845A1 (en) 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008097924A2 (en) 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
SI3825306T1 (sl) 2007-05-01 2023-10-30 Sun Pharmaceutical Industries, Inc. Morfinanske spojine
EP2152709B1 (en) 2007-05-01 2012-02-22 Concert Pharmaceuticals Inc. Morphinan compounds
EP2418211B1 (en) 2008-09-19 2016-03-16 Concert Pharmaceuticals Inc. Deuterated morphinane compounds
SI2397158T1 (sl) 2008-10-30 2016-07-29 Concert Pharmaceuticals Inc. Kombinacija spojin morfinana in antidepresivov za zdravljenje psevdobulbarnih vplivov
JP6525419B2 (ja) 2015-01-15 2019-06-05 株式会社半導体エネルギー研究所 二次電池

Also Published As

Publication number Publication date
EP3825306A1 (en) 2021-05-26
HRP20150848T1 (hr) 2015-09-25
HRP20230745T3 (hr) 2023-10-27
EP3093290B1 (en) 2018-01-24
EP2792662B1 (en) 2016-04-06
HK1178889A1 (en) 2013-09-19
US11473123B2 (en) 2022-10-18
PT3825306T (pt) 2023-07-24
US20140329846A1 (en) 2014-11-06
EP3825306B8 (en) 2023-08-02
BRPI0811478A8 (pt) 2019-10-15
CA3056205C (en) 2023-09-26
HRP20160521T8 (hr) 2016-10-07
ES2523286T3 (es) 2014-11-24
CA2945581C (en) 2021-11-16
PT2522668E (pt) 2015-06-09
HK1201058A1 (zh) 2015-08-21
EP2792662A1 (en) 2014-10-22
PL2792662T3 (pl) 2016-10-31
EP3357923A1 (en) 2018-08-08
CA2945581A1 (en) 2008-11-13
BRPI0811478A2 (pt) 2014-11-04
DK2357183T3 (da) 2015-09-07
US20240117407A1 (en) 2024-04-11
FI3825306T3 (fi) 2023-08-23
BRPI0811478B1 (pt) 2020-12-29
US20210348208A1 (en) 2021-11-11
HK1259133A1 (zh) 2019-11-29
PT2522667E (pt) 2014-11-11
PT2357183E (pt) 2015-09-28
DK3825306T3 (da) 2023-09-11
US9314440B2 (en) 2016-04-19
HUE063526T2 (hu) 2024-01-28
US20180327809A1 (en) 2018-11-15
SI2792662T1 (sl) 2016-10-28
HK1178154A1 (en) 2013-09-06
HUE025569T2 (en) 2016-02-29
HRP20160521T1 (hr) 2016-08-12
PL3825306T3 (pl) 2023-09-11
LT3825306T (lt) 2023-08-10
HUE029782T2 (en) 2017-04-28
ES2545617T3 (es) 2015-09-14
HRP20140903T1 (hr) 2014-11-21
PT2792662T (pt) 2016-07-07
US20240093265A1 (en) 2024-03-21
CA3056205A1 (en) 2008-11-13
CY1117826T1 (el) 2017-05-17
HRP20150809T1 (hr) 2016-02-12
SI3825306T1 (sl) 2023-10-30
EP2357183B1 (en) 2015-07-01
ES2536984T3 (es) 2015-06-01
EP3825306B1 (en) 2023-06-07
US9868976B2 (en) 2018-01-16
CA3208128A1 (en) 2008-11-13
HK1155442A1 (en) 2012-05-18
EP3093290A1 (en) 2016-11-16
ES2951028T3 (es) 2023-10-17
DK2792662T3 (da) 2016-07-25
EP3357923B1 (en) 2019-11-13
ES2577477T3 (es) 2016-07-15
BRPI0811478B8 (pt) 2021-05-25
US20170037449A1 (en) 2017-02-09
EP2357183A1 (en) 2011-08-17
PL2357183T3 (pl) 2015-12-31

Similar Documents

Publication Publication Date Title
AU2008247818B2 (en) Morphinan compounds
US20240117407A1 (en) Morphinan compounds
AU2013270618B2 (en) Morphinan compounds
EP3632916B1 (en) Morphinan compounds
AU2018204333B2 (en) Morphinan compounds